Mylan Says Fed. Circ. Must Nix Ruling That Upheld Biogen IP
Mylan wants a Federal Circuit panel to reconsider a decision affirming its failed Patent Trial and Appeal Board challenge to a Biogen patent on the blockbuster multiple sclerosis drug Tecfidera, saying...To view the full article, register now.
Already a subscriber? Click here to view full article